Riverview Trust Co Acquires Shares of 368 Charles River Laboratories International, Inc. (NYSE:CRL)

Riverview Trust Co acquired a new stake in Charles River Laboratories International, Inc. (NYSE:CRL) in the 1st quarter, according to the company in its most recent filing with the SEC. The fund acquired 368 shares of the medical research company’s stock, valued at approximately $100,000.

Several other institutional investors have also recently bought and sold shares of the business. APG Asset Management US Inc. acquired a new stake in shares of Charles River Laboratories International in the 4th quarter valued at $2,321,000. Norges Bank acquired a new stake in shares of Charles River Laboratories International in the 4th quarter valued at $101,319,000. abrdn plc increased its stake in shares of Charles River Laboratories International by 872.0% in the 4th quarter. abrdn plc now owns 121,807 shares of the medical research company’s stock valued at $28,795,000 after buying an additional 109,275 shares during the period. Regency Capital Management Inc. DE acquired a new stake in shares of Charles River Laboratories International during the fourth quarter worth $3,703,000. Finally, Principal Financial Group Inc. grew its stake in shares of Charles River Laboratories International by 30.8% during the fourth quarter. Principal Financial Group Inc. now owns 152,537 shares of the medical research company’s stock worth $36,060,000 after purchasing an additional 35,921 shares during the period. Institutional investors own 98.91% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. Mizuho started coverage on Charles River Laboratories International in a research note on Friday, June 7th. They set a “neutral” rating and a $235.00 price objective for the company. Robert W. Baird cut their price target on Charles River Laboratories International from $282.00 to $270.00 and set an “outperform” rating on the stock in a report on Friday, May 10th. TD Cowen cut their price target on Charles River Laboratories International from $260.00 to $228.00 and set a “hold” rating on the stock in a report on Monday, May 13th. TheStreet upgraded Charles River Laboratories International from a “c+” rating to a “b-” rating in a report on Friday, March 1st. Finally, StockNews.com lowered Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Friday, June 14th. Six investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $256.38.

Insider Activity

In other news, EVP Joseph W. Laplume sold 1,304 shares of the company’s stock in a transaction that occurred on Friday, May 10th. The stock was sold at an average price of $226.97, for a total value of $295,968.88. Following the transaction, the executive vice president now owns 23,276 shares of the company’s stock, valued at $5,282,953.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 1.30% of the stock is owned by company insiders.

Charles River Laboratories International Price Performance

Shares of NYSE CRL opened at $206.39 on Wednesday. The business’s 50 day moving average price is $221.44 and its two-hundred day moving average price is $232.84. The company has a market cap of $10.63 billion, a PE ratio of 24.28, a price-to-earnings-growth ratio of 2.00 and a beta of 1.40. The company has a quick ratio of 1.37, a current ratio of 1.75 and a debt-to-equity ratio of 0.73. Charles River Laboratories International, Inc. has a twelve month low of $161.65 and a twelve month high of $275.00.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Thursday, May 9th. The medical research company reported $2.27 EPS for the quarter, beating the consensus estimate of $2.05 by $0.22. Charles River Laboratories International had a return on equity of 15.16% and a net margin of 10.81%. The company had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $997.24 million. On average, analysts predict that Charles River Laboratories International, Inc. will post 11 EPS for the current year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).